Amgen (NASDAQ:AMGN) executives said the company delivered a “strong first quarter” and remains positioned to meet its goals ...

Amgen stock toppled Friday as investors digested its "generally in-line" first-quarter report and expansion in the obesity treatment space.

Amgen AMGN reported first-quarter adjusted earnings of $5.15 per share, which beat the Zacks Consensus Estimate of $4.73 per ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

The S&P 500 and Nasdaq 100 hit fresh records Friday morning; the Dow turned negative by midday. Apple's 4.5% post-earnings ...

The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...

Apple leads Nasdaq higher at open, Amgen drags on Dow Wall Street stocks have opened higher, helped by strong early gains for ...

Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, ...

The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...